^
Association details:
| Biomarker: | RRM1 underexpression |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | azacitidine (DNA methylation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine
Excerpt:
The study included 123 patients diagnosed with MDS per the WHO 2008/2016 classification; 98 of them were treated with AZA…The median mRNA levels of RRM1 were 4.2 times higher in non-responders (p=0.019) in comparison to responders….MDS patients with low RRM1 levels had a better response to AZA-treatment.
DOI:
10.1182/blood-2019-126426
